JAMA Trial Tests Tenecteplase Before Thrombectomy in Late-Window MCA Stroke

A patient arrives well beyond the usual thrombolysis window, still a thrombectomy candidate, with a proximal middle cerebral artery occlusion on imaging. The question in the angio suite is simple enough: do you give IV tenecteplase on the way to endovascular treatment, or skip it and go straight to the catheter?

A phase 3 randomized superiority trial from China, published in JAMA, takes direct aim at that workflow question. The study compared intravenous tenecteplase before endovascular treatment (EVT) with EVT alone in patients treated 4.5 to 24 hours after onset of ischemic stroke due to proximal middle cerebral artery occlusion.

Why this matters to US stroke teams is obvious. Tenecteplase is easier to give than alteplase, and the role of so-called bridging thrombolysis keeps getting revisited as thrombectomy systems mature. This trial asks whether, in a late-window population with a specific large-vessel occlusion, adding tenecteplase before EVT improves outcomes enough to justify the extra step and any added bleeding risk.

What the trial actually found

The paper describes a phase 3 randomized superiority trial conducted in China. Investigators enrolled patients with ischemic stroke caused by proximal middle cerebral artery occlusion who presented between 4.5 and 24 hours after symptom onset and were candidates for EVT. Participants were assigned to receive intravenous tenecteplase before EVT or EVT alone.

That design matters. This was not a broad all-comers stroke trial. It focused on a defined large-vessel occlusion, in a late time window, and tested a pragmatic question that maps closely to real-world transfer and angiography workflows.

From the summary provided by JAMA, the trial assessed both efficacy and adverse events. The article’s central comparison was straightforward: tenecteplase plus EVT versus EVT alone.

What we can say from the source material is limited to that framework and outcome focus. The summary does not provide the sample size, the tenecteplase dose, the primary endpoint definition, effect estimates, or the detailed safety results. It also does not name the trial investigators in the material provided here. So the safe read is this: JAMA judged the trial important enough to publish as a phase 3 superiority study asking whether pretreatment with IV tenecteplase changes outcomes before thrombectomy in late-window proximal MCA stroke.

Worth knowing. The population here was narrower than the broad category of "large-vessel occlusion stroke": patients had proximal middle cerebral artery occlusion and were treated 4.5 to 24 hours after onset.

Clinically, tenecteplase is a fibrinolytic given as an IV bolus, which is one reason stroke programs keep revisiting it in door-to-needle and drip-and-ship protocols. In a patient already headed for EVT, the hoped-for upside is early reperfusion or clot softening before the device ever crosses the lesion. The tradeoff, as always, is bleeding.

How this lands in practice

For US physicians, this is less about a new drug than about sequencing. If you run a primary stroke center, staff a comprehensive center, or take transfer calls, the practical issue is whether adding IV tenecteplase in this late-window subgroup helps enough to change the standard pre-EVT routine.

If the full trial results show a clear functional benefit without an unacceptable safety penalty, that would strengthen the case for a bridging strategy in carefully selected patients who present beyond 4.5 hours yet still meet imaging and EVT criteria. It could also push programs to tighten protocols so the bolus does not delay groin puncture.

If the signal is neutral, mixed, or offset by harm, the opposite lesson follows: skip the extra step and move directly to thrombectomy in this setting.

That distinction matters because stroke workflow is unforgiving. Any intervention added before EVT has to earn its place. A theoretically useful bolus is not enough if it slows transfer to the suite, complicates handoffs, or adds hemorrhagic risk without a meaningful improvement in patient-centered outcomes.

US teams should also be careful not to overgeneralize. This trial, as summarized, speaks to a late-window proximal MCA population. It does not automatically settle questions about earlier windows, internal carotid occlusions, basilar occlusions, wake-up strokes more broadly, or patients who are not EVT candidates.

The asterisks

The biggest limitation here is the source material itself. The summary supplied by JAMA does not include the numbers physicians usually want before changing practice: how many patients were enrolled, what dose of tenecteplase was used, how efficacy was measured, how large any benefit was, and what happened with symptomatic intracranial hemorrhage and mortality.

Generalizability is another issue. The trial was conducted in China, and systems of care, transfer patterns, imaging selection, time-to-puncture intervals, and background stroke protocols can differ from US practice. Even a positive result may not transplant neatly to every American stroke network.

There is also the problem of scope. Proximal MCA occlusion is common, but it is still a selected anatomy. The summary does not tell us whether the findings were consistent across age groups, stroke severity, onset pattern, collateral status, or transfer versus direct-arrival patients.

And because this was framed as a superiority trial, the details matter. A superiority design asks more than whether tenecteplase is reasonable; it asks whether it is better than EVT alone. Without the actual effect size and confidence intervals, clinicians should resist reading more certainty into the paper than the available summary supports.

What to watch next

The next step is straightforward: read the full paper, not just the headline. Stroke neurologists and interventional teams will want the hard numbers on functional outcomes, reperfusion, hemorrhage, and workflow timing before rewriting order sets.

If the results are convincingly positive, expect this trial to be pulled quickly into discussions around institutional bridging-thrombolysis protocols for late-window thrombectomy candidates with proximal MCA occlusion. If the benefit is narrow or safety is a concern, the paper may still shape decision-making by telling teams where tenecteplase does not add enough.

Either way, this is the kind of trial that can influence Monday-morning protocol meetings. The question is practical, the comparator is real, and for stroke systems trying to move fast without skipping benefit, that is usually where practice starts to shift.